>PROKKA_00001 Dihydroorotase
VLLIKNGKVLTMTDKKHVNDCILINNGKIEKIAEKIEINNESIEVIDAKGGWVMPGIIDA
HCHIGIMEEGIKFEGMDLNEYSSAITPHLRAIDGINPRDLAFQSAIEAGITTVMTGMGSS
NPIGGQFAIIKTYGKSVDEMVVKAPAALKIAFGENPKSIFGKKGSMPITRMGTAALIRET
LYKAKNYMNRKEEALKEGKIFDIDIKMESIIPVLKKEIPLKAHAHRSDDILTAIRIAKEF
DLKLTIDHGTEAHLVADYIKESGFPVIAGPNMNFRGKVETKNRSYNTTKILQEKEILYAM
ITDHPVVPIEFLPISAALAVKNGLKEEDALKAITINPAKILGIEHRVGTLDVGKEADICI
YNDNPLNMNSKNMYTIISGNIVYDYNKNL*
>PROKKA_00002 putative membrane protein
MHFCRKCGNKLQKNSKCCNTCGSELEKIHKEEINSITDKDKLLDNEIFNDEHILEHKEEP
LEIIRKFNLIKKIKENKVFLIAILILIIIVTPLIKNPIKNFVIRKNPANWLVYAADKCKK
SDTLDTVSDFKIKSAAESQEFMNYKDIENIIEQCTLRVNNKINKKTNERYSKVSLIYKEE
NILNGEFYSNKEYMAISMPQLYKDIMYIKWEDVNKLINNNKENKDISETIDPKNYENVLN
IKKSKYYDNVNGDYKEFFYNIMDDYVKRGDKVDIVTKQEDKEKTIKCDEIVVHLDNERII
KILNAFFQKMSKDENLKLLVRDKVFEFLSTVQKNQDLNKFNLSKEDADNIKRDFDSEYDS
FMKELSHVEKIDKKASNGKINSLTKVKIDSRNYIRGLQSEISIDKKKTSFNFISNTVINS
IDSKLHIKKIPKERAKDISKFTAKDREDIVIEMENNIQKIMFSKLNIK*
>PROKKA_00003 hypothetical protein
MESTQIMSFSREELIKQLIKETKLISAKGVQETLKDIFTNTFKGMLEAKLDNHLGYSDLI
LPRDIEGSFDLQVMKKNQNHILIVFDKFI*
>PROKKA_00004 Botulinum neurotoxin type B precursor
MIIWTLIDINGKIKSVFFEYSIKEDISEYINRWFFVTITNNSDNAKIYINGKLESHIDIR
DIREVIANDEIIFKLDGNIDRTQFIWMKYFSVFNTELSQSNIEERYKIQSYSEYLKDFWG
NPLMYNKEYYMFNAGNKNSYIKLKKDSPVGEILTRSKYNQNSKYINYRDLYIGEKFIIRR
KSNSQSINDDIVRKEDYIYLDFFNLNQEWRVYIYKYFKKEEEKLFLAPISDSDDFYNTIQ
IKEYDEQPTYSCQLLFKKDEESTDEIGLIGIHRFYESGIVFKEYKDYFCISKWYLKEVKR
KPYNSKLGCNWKFIPKDEGWTE*
>PROKKA_00005 Botulinum neurotoxin type B precursor
VERKKGIFANLIIFGPGPVLNENETIAIGIQNHFASREGFGGIMQMKFCPEYVSVFNNVQ
ENKGASIFNRRGYFSDPALILMHELIHVLHGLYGIIVNDLPIVPNEKKFFMQSTDAIQAE
ELYTFGGQDPSIISPSTDKSIYDKVLQNFRGIVDRLNKVLVCISDPNININIYKNKFKDK
FVEDSEGKYSIDVESFDKLYKSLMFGFTETNIAENYKIKTRASYFSDSLPPVKIKNLLDN
EIYTIEEGFNISDKNMEKEYRGQNKAINKQAYEEISKEHLAIYKIQMCKSVKAPGICIDV
DNEDLFFIADKNSFSDDLSKNERIAYNTQNNYIENDFSINELILDTDLISKIELPSENTE
SLTDFNVYVPEYKKQLAIKKIFTDENTIFQYLYSQTFPLDIRDISLTSSFDDALLFSNKV
YSFFSMDYIKTANKVVEAGLFAGWVKQIVDDFVIEANKSSTMDKIADISLIVPYIGLALN
VGNETAKGNFENAFEIAGASILLEFIPELLIPVVGAFLLESYIDNKNKIIETINSALTKR
DEKWIDMYGLIVAQWLSTVNTQFYTIKEGMYKALNYQAQALEEIIKYKYNIYSEKERSNI
NIDFNDVNSKLNEGINQAIDNINNFINECSVSYLMKKMIPLAVEKLLDFDNTLRKNLLNY
IDENKLYLIGSAEYEKSKVDKYLKTSIPFDLSMYTNNTILIEIFNKYNSDILNNIILNLR
YRDNKLIDLSGYGAKVEVYDGVKLNDKNQFKLTSSANSKIRVIQNQNIIFNSMFLDFSVS
FWIRIPKYKNDGIQNYIHNEYTIINCMKNNSGWKYLLGVI*
>PROKKA_00006 Botulinum neurotoxin type B precursor
MPVTINNFNYNDPIDNNIIIMMEPPFARGMGRYYKAFKITDRIWIILERYTFGYKPEDFN
KSSGIFNRDVWEYYDPDYLNTNDKKNIFLQTMIKLFNRIKSKPLGEKLLEMIINGIPYLG
DRRVPLE*
>PROKKA_00007 Botulinum neurotoxin type A precursor
MCVEINLGEWLDMNINDNLSINSPVDNKNVVVVRARKTDTVFKAFKVAPNIWVAPERYYG
ESLSIDEEYKVDGGIYDSNFLSQDSEKDKFLQAIITLLKRINSTNAGEKLLSLISTAIPF
PYGYIGGGYYAPNMITFGSAPKSNKKLNSLISSTIPFPYAGYRETNYLSSEDNKSFYASN
IVIFGPGANIVENNTVFYKKEDAENGMGTMTEIWFQPFLTYKYDEFYIDPAIELIKCLIK
SLYFLYGIKPSDDLVIPYRLRSELENIEYSQLNIVDLLVSGGIDPKFINTDPYWFIDNYF
SNAKKVFEDHRNIYETEIEGNNAIGNDIKLRLKQKFRININDIWELNLNYFSKEFSIMMP
DRFNNALKHFYRKQYYKIDYPENYSINGFVNGQINAQLSLSDRNQDIINKPEEIINLLNG
NNVSLMRSNIYGDGLKSTVDDFYSNYKIPYNRAYEYHFNNSNDSSLDNVNIGVIDNIPEI
IDVNPYKENCDKFSPVQKITSTREINTNIPWPINYLQAQNTNNEKFSLSSDFVEVVSSKD
KSLVYSFLSNVMFYLDSIKDNSPIDTDKKYYLWLREIFRNYSFDITATQEINTDCGINKV
VTWFGKALNILNTSDSFVEEFQNLGPISLINKKENLSMPKIEIDEIPNSMLNLSFKDLSE
NLFNIFSKNNSYFEKIYYDFLDQWWTQYYSQYFDLICMAKRSVLAQESLIKKIIQKKLSY
LIGNSNISSDNLALMNLTTTNTLRDISNESQIAMNNVNNFLNNVAICVFQTNIYPKFISF
MEQCINNINKNTREFIQKCTNITENEKLQLINQNIFSSLDFDFLNIENLKSLFNSETGLL
IKEETSPYELVLYAFQEPGNNAIGDASGKNTSIEYSKDIGLVYGINSDALYLNGSNQSIS
FSNDFFENGLTNSFSIYFWLRNLGKDTIKSKLIGSKEDNCGWEIYFQDTGLVFNMIDSNG
NEKNIYLSDVSNNSWHYITISVDRLKEQLLIFIDDNLVANESIKEILNIYSSNTISLVNE
NNPIYVEGLSILNRSITSEEVVNNYFTYLNNSYIRDISGERLEYNKTYELYNYVFPESSL
YEVTENNNIYLSIKNTNNLNIQGAKFKLINIDANKQYVQKWDEGVVCLLGDEEKYVDISS
ENNRIQLVSSKDTAKRIIFNNDIFRPNCLTFAYNNKYLSLSLRDRNYNWMICNNNDNIPK
AAHLWALKGI*
>PROKKA_00008 transcriptional regulator BotR, P-21
MNKLFLQIKMLKNDNEEFQEIFKHFEKTINIFTRKYNIYDNYNDILYHLWYTLKKVDLSN
FNTQNDLERYISRTLKRYCLDICNKRKIDKKIIYNSEIADKKLSLIANSYSSYSEFEFND
LISILPDDQKKIIYMKFVEDIKEIDIAKKLNISRQSVYKNKIMALERLEPILKKLINM*
>PROKKA_00009 hypothetical protein
MEHYSVIQNSLNDKIVTISCKADTNLFFYQVAGNVSLFQQTRNYLERWRLIYDSNKAAYK
IKSMDIHNTNLVLTWNAPTHNISTQQDSNADNQYWLLLKDIGNNSFIIASYKNPNLVLYA
DTVARNLKLSTLNNSNYIKFIIEDYIISDLNNFTCKISPILDRNKVVQQVDMTNLNVNLY
TWDYGRNQKWTIRYNEEKAAYQFFNTILSNGVLTWIFSNGNTVRVSSSNDQNNDAQYWLI
NPVSDTDETYTITNLRDTTKALDLYNSQTANGTAIQVFNYHGDDNQKWNIRNP*
>PROKKA_00010 HA 17 kDa subunit
MSVERTFLPNGNYNIKSIFSGSLYLNPVSKSLTFSNESSANNQKWNVEYMAENRCFKISN
VAEPNKYLSYDNFGFISLDSLSNRCYWFPIKIAVNTYIMLSLNKVNELDYAWDIYDTNEN
ILSQPLLLLPNFDIYNSNQMFKLEKI*
>PROKKA_00011 Hemagglutinin components HA-22/23/53 precursor
MNSSIKKIYNDIQEKVINYSDTIDLADGNYVVRRGDGWILSRQNQILGGSVISNGSTGIV
GDLRVNDNAIPYYYPTPSFNEEYIKNNIQTVFTNFTEANQIPIGFEFSKTAPSNKNLYMY
LQYTYIRYEIIKVLQHEIIERAVLYVPSLGYVKSIEFNPGEKINKDFYFLTNDKCILNEQ
FLYKKILETTKNIPTNNIFNSKVSSTQRVLPYSNGLYVINKGDGYIRTNDKDLIGTLLIE
AGSSGSIIQPRLRNTTRPLFTTSNDTKFSQQYTEERLKDAFNVQLFNTSTSLFKFVEEAP
SDKNICIKAYNTYEKYELIDYQNGSIVNKAEYYLPSLGYCEVTNAPSPESEVVKMQVAED
GFIQNGPEEEIVVGVIDPSENIQEINTAISDNYTYNIPGIVNNNPFYILFTVNTTGIYKI
NTQNNLPPLKIYEAIGSGNRNLQAGNLCNNNIKAINYITGVDDPNTKSYLVVLLNKDKNY
YIRVPQTSPNIENQIKFKREEGDLRNLMNSSVNIIDNLNSTGAHYYTRQSPDVGNYISYE
FTVPGNFNNKDTSNIRLYTSNNQGIGTLFRVIETIDGYKLIGIRQNLHLLNNTNSIRLLN
GAIYILKVEVTELNNYNIRLHIDITN*
>PROKKA_00012 Transposase
VAKKIYSTELKLEIVKKYLSDNISFGMLAQECNINKEDIQKWFVVYREHGEAVLSTVNGT
YTRDFKINVVEHIHNCSD*
>PROKKA_00013 hypothetical protein
MGTRLKELSLIYKNNTLNEDDKKNIEYEAKSLLDNMYFTIKNTKFNGKNLFTGEKLNIQG
STYNTDIKLMDFKVPKEDSIFIGNNKSSNESHTIKISDTKIDVILKKYNLEKANKIIFYE
SEMVDKHNIKTVFTSKYGYKNNANIDIVNVSNNVNKMFSINGTINDNSEVKGYLQEEDNK
LIGNININDKEYNIQLETTMEYALKTNLNSIKTTIINKNNHTFRGNTSIVDIQDNSGMTY
TSKEITIYEFKEIIANNKSNNKNKQIVFELSNNKKITFDINNKDINLYIFDEEYNSFDIS
DILNSSNIIEEKVLSELNNYQNYIGIKTNELEYKLNFEQNNQIL*
>PROKKA_00014 hypothetical protein
MKLSTNKKVNIAADSPSEIERINRINTSVRSRNIAVRIFKKEYLYYK*
